key: cord-0727089-b2exzzgx
authors: Hall, David J.; Schulte, Jefree J.; Lewis, Erik E.; Bommareddi, Swaroop R.; Rohrer, Charles T.; Sultan, Samir; Maloney, James D.; DeCamp, Malcolm M.; McCarthy, Daniel P.
title: Successful Lung Transplantation for Severe Post COVID-19 Pulmonary Fibrosis
date: 2021-11-05
journal: Ann Thorac Surg
DOI: 10.1016/j.athoracsur.2021.10.004
sha: c80f7d32dbcd381841905151feffccb6f11f81e6
doc_id: 727089
cord_uid: b2exzzgx

Lung transplantation has been well described for COVID-19 patients in the acute setting, but less so for the resulting pulmonary sequelae. We share one of the first cases of lung transplantation for post COVID-19 pulmonary fibrosis. A 52-year-old female developed COVID-19 in July 2020 and mounted a partial recovery, but went on to have declining function over the ensuing three months and developed fibrocystic lung changes. She underwent bilateral lung transplantation and recovered rapidly, was discharged home POD 14, and has done well in follow-up. We demonstrate that lung transplantation is an acceptable therapy to treat post COVID-19 pulmonary fibrosis.

Over the past year, the lung failure and transplantation community has met unprecedented challenges in the care of patients affected by COVID-19. The pandemic has not only led to an increase in patients with acute lung injury, but also a population of survivors who develop the long-term sequelae of COVID-19. Many of the early lung transplants for COVID-19 were performed for patients with acute lung failure on extracorporeal membrane oxygenation (ECMO) support rather than for long-term effects of the disease. [1] [2] [3] [4] [5] [6] Herein we report one of the first cases of lung transplantation for post COVID-19 pulmonary fibrosis.

An otherwise healthy 52-year-old female developed COVID-19 pneumonia in July 2020. At baseline she was worked full-time and jogged several miles per day. Following infection, she progressed to severe acute respiratory distress syndrome and was treated with remdesivir, tocilizumab, and corticosteroids. She spent seven days on BIPAP with a fraction of inspired oxygen (FiO2) of 100% at rest followed by an additional five weeks on CPAP alternating with humidified high flow nasal cannula (HFNC). After six weeks, she was discharged to a long-term assisted care facility where she wore HFNC with an FiO2 of 70% at rest and BIPAP with an FiO2 of 50% during short walks and time on a recumbent bicycle. Follow up COVID-19 PCR testing was negative in August 2020 and she additionally became COVID IgG Ab positive.

Unfortunately, she developed progressive pulmonary fibrosis prompting referral for consideration of advanced lung failure therapies.

She was transferred to our institution in October 2020 for transplant evaluation. Imaging Following less than 24h of ECMO, she underwent bilateral sequential lung transplantation on central venoarterial ECMO via bilateral thoracosternotomy. Intraoperatively, there were no significant pleural adhesions, but robust mediastinal and hilar lymphadenopathy with stigmata of acute inflammation was identified. The procedure was uncomplicated and ischemic times were 268 min for the left lung and 391 min for the right lung. Post-operatively, she did not require vasopressor support. Bronchoscopy on POD1 demonstrated intact anastomoses, and her P/F ratio was >400. She was extubated early on POD2 and the remainder of her stay was unremarkable, with quick progression and discharge to home on POD14. She is now over ten months status post lung transplantation and has done well with no evidence of rejection and stable pulmonary function testsmost recent FEV1 1.81L (86% predicted) and FVC 2.26L (89% predicted).

Lung transplantation for pulmonary fibrosis secondary to severe COVID-19

Lung transplantation as therapeutic option in acute respiratory distress syndrome for coronavirus disease 2019-related pulmonary fibrosis

Lung Transplantation for elderly patients with end-stage COVID-19 Pneumonia

Lung transplantation for COVID-19-associated acute respiratory distress syndrome in a PCR-positive patient

Histopathologic Findings in the Explant Lungs of a Patient with COVID-19 Treated with Bilateral Orthotopic Lung Transplant

Pulmonary Pathology of COVID-19 Following 8 Weeks to 4 Months of Severe Disease: A Report of Three Cases, Including One With Bilateral Lung Transplantation